Onxeo to Present New Preclinical Data at AACR 2021
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors
Introducing OX400, a new generation of PARP interfering cancer drug
candidates
Paris (France), April 8, 2021 – 6:00 pm CEST - Onxeo S.A. (Euronext Growth Paris: ALONX, First North
Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the
development of innovative drugs targeting tumor DNA Damage response (DDR), today announced the
presentation of preclinical data confirming the differentiated antitumoral properties of the drug candidates
generated by platON™, its patent-protected platform of decoy-agonists of the DNA Damage Response, in eposter sessions during the American Association for Cancer Research (AACR 2021) virtual annual meeting on April
10, 2021.
The first e-poster supports the ability of AsiDNA™, the Company’s first-in-class DNA Damage Response (DDR)
inhibitor, to prevent resistance to KRAS inhibitors (KRASi) emerging from drug-tolerant persister cells (DTC).
Novel therapies targeting the inhibition of KRAS, an oncogenic protein present in a third of cancers, have shown
very promising clinical results especially in non-small cell lung cancer. However, acquired resistance hinders their
efficacy. Combining AsiDNA™ to KRASi could be an additional development opportunity for AsiDNA™, in the
context of its use to prevent acquired resistance to targeted therapies.
The second e-poster describes the mechanism of action of the molecules of the new OX400 family, specifically
designed to interfere with PARP signaling and display immunomodulatory properties and metabolic effects.
Judith Greciet, Chief Executive Officer of Onxeo, commented: “Pharmaco-tolerant cells are a well-established
cause of resistance to TKIs, and, as we already demonstrated last year, to PARP inhibitors. We have generated
new data demonstrating that these cells are also involved in resistance to KRAS inhibitors and confirmed the
efficacy of AsiDNA™ on these cells thus preventing or even reversing tumor regrowth. These results open the door
for another potential combination with these innovative compounds which show high efficiency but struggle with
resistance issues. In parallel, we continue to optimize the efficacy profile of the next candidates from the OX400
family, while keeping the established benefits shared by all our platON™-sourced compounds in terms of safety
and absence of resistance. Our new results confirm that, by trapping and exhausting specifically PARP, OX400
compounds have the potential to modulate the immune response and wear out the tumor cell metabolism. We
will continue to explore these original properties.”